European Journal of Dermatology
MENUTolerance of methotrexate in a daily practice cohort of adults with atopic dermatitis Volume 28, numéro 2, March-April 2018
Tableaux
1 Allergy and Clinical Immunology Department, University Hospital Lyon Sud, Pierre Bénite, France
2 CIRI (International Centre for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, 21 Avenue Tony Garnier, 69007 Lyon, France
- DOI : 10.1684/ejd.2018.3231
- Page(s) : 266-7
- Année de parution : 2018
Despite the increasing incidence of atopic dermatitis (AD), systemic treatments are still limited. Oral cyclosporine A (CsA) is the only approved drug for patients with moderate-to-severe AD failing to respond to topical agents. However, its use is limited by toxicity, which hampers the long-term management of AD. Methotrexate (MTX) could be a valuable alternative, with its well-known use by dermatologists, limited cost, and good safety profile in patients with psoriasis [1]. Having previously shown [...]